NDAORALTABLETPriority Review
Approved
Nov 2021
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
21
Mechanism of Action
Cytomegalovirus pUL97 Kinase Inhibitors
Pharmacologic Class:
Cytomegalovirus pUL97 Kinase Inhibitor
Clinical Trials (5)
A Study of Maribavir in Adults With Kidney Failure Who Have a Cytomegalovirus (CMV) Infection After Transplantation
Started Nov 2025
10 enrolled
Cytomegalovirus (CMV)Kidney DiseaseKidney Failure
A Study of Maribavir in Adults With Post-transplant Cytomegalovirus (CMV) Infection in Belgium
Started Feb 2025
75 enrolled
Cytomegalovirus (CMV)
A Study of Maribavir in Chinese Adults With Cytomegalovirus (CMV) Infections
Started Dec 2024
20 enrolled
Cytomegalovirus (CMV)
A Study of LIVTENCITY (Maribavir) in Adults With Cytomegalovirus (CMV) Infection After Transplantation in South Korea
Started Nov 2024
168 enrolled
Cytomegalovirus (CMV)
A Study of Maribavir in Adults With Post-transplant Cytomegalovirus (CMV) Infection
Started Oct 2024
265 enrolled
Cytomegalovirus (CMV)
Loss of Exclusivity
LOE Date
Oct 11, 2043
214 months away
Patent Expiry
Oct 11, 2043
Exclusivity Expiry
Nov 23, 2028